Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?
Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease.